Alkermes plc (ALKS) Announces Initiation Of Second Phase 2 Clinical Study Of ALKS 3831, A Novel Broad-Spectrum Oral Antipsychotic
6/2/2014 9:04:40 AM
DUBLIN, Ireland--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia. The randomized, double-blind, active-controlled study will assess ALKS 3831’s efficacy, safety and tolerability in treating schizophrenia in patients with co-occurring alcohol use disorder, compared to olanzapine, an approved and widely used atypical antipsychotic medicine. More than one-third of patients with schizophrenia have a co-occurring alcohol use disorder,1 a population that is commonly excluded from clinical trials and is often undertreated.
Help employers find you! Check out all the jobs and post your resume.
comments powered by